FDA CoI Policies For Advisory Committees Viewed As Fair, Credible – Study
This article was originally published in The Gray Sheet
Executive Summary
Advisory committee members and meeting attendees perceive FDA's management of real or potential conflicts of interest among committee members as generally fair and credible, a 1study funded by the Joint Institute for Food Safety & Applied Nutrition says
You may also be interested in...
FDA Advisory Panel CoI Statements Should Be More Transparent – NEJM
FDA may need to change its conflict-of-interest policies for advisory panels, a column in the July 14 New England Journal of Medicine proposes
FDA Advisory Panel CoI Statements Should Be More Transparent – NEJM
FDA may need to change its conflict-of-interest policies for advisory panels, a column in the July 14 New England Journal of Medicine proposes
FDA Silicone Breast Implant Review Moves Forward, Despite CoI Objections
Michael Miller's contributions to the FDA General & Plastic Surgery Devices Panel's recent silicone-filled breast implant review outweigh any alleged conflict of interest, the agency maintains